Overall, this study shows that miR-1304-5p is an NB tumor suppressor and regulator of ALK TKI response, targeting oncogenic NRAS and paving the way for the use of miRNA- or FTI-based ALK TKI combination treatments for aberrant ALK-expressing NB. This evidence concerns the gene ALK and neoplasm.